Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Financials
Key financial figures for Amneal Pharmaceuticals, Inc. Class A Common Stock (Q2 2026).
Amneal Pharmaceuticals, Inc. reported revenue of $796.2 million for Q2 FY2026, up 9.9% from the same period a year earlier. Net income was $57.7 million, or $0.18 per share. Operating margin came to 18.33%, against 15.37% a year earlier. Free cash flow for the period was -$64.9 million. Across the last 5 reported quarters, quarterly revenue has risen from $724.5 million in Q2 FY2025 to $796.2 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Amneal Pharmaceuticals, Inc. are on the SentiSense financials page.
- Revenue
- $796M
- Net Income
- $58M
- EPS
- $0.18
- Total Assets
- $3.8B
- Operating Cash Flow
- -$19M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $796M | $58M | $0.18 | 18.33% | -$65M |
| Q1 FY2026 | $723M | $62M | $0.19 | 19.77% | -$43M |
| Q4 FY2025 | $814M | $35M | $0.11 | 14.06% | $87M |
| Q3 FY2025 | $785M | $2M | $0.01 | -0.01% | $103M |
| Q2 FY2025 | $725M | $22M | $0.07 | 15.37% | $57M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $3.0B | $72M | $0.22 | 14.02% | $270M |
| FY2024 | $2.8B | -$117M | -$0.38 | 8.92% | $220M |
| FY2023 | $2.4B | -$84M | -$0.48 | 8.54% | $276M |
Frequently asked questions
What was Amneal Pharmaceuticals, Inc.'s revenue last quarter?
Amneal Pharmaceuticals, Inc. reported revenue of $796.2 million for Q2 FY2026, up 9.9% from the same period a year earlier.
Is Amneal Pharmaceuticals, Inc. profitable?
Yes. Amneal Pharmaceuticals, Inc. reported net income of $57.7 million for Q2 FY2026, a net margin of 7.24% on revenue.
How has Amneal Pharmaceuticals, Inc.'s margin trended?
Operating margin was 18.33% in Q2 FY2026, compared with 15.37% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Amneal Pharmaceuticals, Inc. generate?
Amneal Pharmaceuticals, Inc. generated free cash flow of -$64.9 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Amneal Pharmaceuticals, Inc. Class A Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.